Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation

Journal of Medical Economics

Volumn 16, Issue 10, 2013, Pages 1193-1202

  Amin, Alpesh ^a   Stokes, Michael ^b   Wu, Ning ^b   Gatt, Elyse ^b   Makenbaeva, Dinara ^c   Wiederkehr, Daniel ^d   Boulanger, Luke ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNITED BIOSOURCE CORPORATION   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

Anticoagulants; Costs; Medical cost reduction; Resource use; Stroke

Indexed keywords

APIXABAN; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COST; DRUG DETERMINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICARE; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; COST SAVINGS; COSTS AND COST ANALYSIS; FEMALE; HEMORRHAGE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; STROKE; UNITED STATES; WARFARIN;

EID: 84884554827     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.828064     Document Type: Article

References (27)

1. Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ 2008;11:281-98
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119-25 (Pubitemid 44420743)
3. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008;92:17-40, ix (Pubitemid 350182405)
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147:1561-4 (Pubitemid 17138836)
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
6. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40:235-40
7. Stettin GD. Treatment of nonvalvular atrial fibrillation. West J Med 1995;162:331-9
8. Ali A, Bailey C, Abdelhafiz AH. Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. Aging Dis 2012;3:339-51
9. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-56 (Pubitemid 44337788)
10. Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health 2012;15:240-8
11. Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13:1375-85
12. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-8
13. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323:1505-11
14. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62
15. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8
16. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55
17. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12
18. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
19. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-58
20. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012;15:776-85
21. Britton A, McKee M, Black N, et al. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy 1999;4:112-21 (Pubitemid 29186862)
22. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus aspirin in patients at risk of ischaemic events. Am J Med 1999;107:568-72
23. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
24. Berg AM. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:570; author reply 570-1
25. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
26. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70
27. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19